Six patients with large uterine fibroids were given a single subcutaneous implant of an LHRH analogue (goserelin 3 -5 mg) prior to elective hysterectomy. Overall fibroid volume decreased by 30-47% within six weeks of implantation. All patients reported improvement in their symptoms ofpressure and pain, and were rendered amenorrhoeic prior to surgery.
INTRODUCTION
Goserelin, a high potency luteinizing hormone -releasing hormone (LHRH) analogue is available as a slow release subcutaneous implant (Zoladex ICI), which has been shown to produce consistent, reversible suppression of the pituitaryovarian axis.1 The release of follicle stimulating hormone and luteinizing hormone from the pituitary gland is under the control of pulsatile release of LHRH from the hypothalmus. Continuous administration of LHRH analogues causes pituitary gonadotrophes to become desensitised, which induces a state of hypogonadotrophic hypogonadism, a process known as pituitary down -regulation. As a result of this oestrogen output from the ovary decreases and serum oestrogen levels fall to values in the postmenopausal range. LHRH analogues are increasingly advocated in the management of common oestrogen -dependent gynaecological conditions, notably uterine fibroids,2 3 endometriosis4,5 and menorrhagia,6 and may also be effective in the management of metastatic breast cancer.7 Recent work2,3 has shown the effectiveness of both buserelin and goserelin in shrinking uterine fibroids to about 50 % of their original size (assessed by ultrasonic measurement), but both these studies showed regrowth of the fibroids to their former size within months of stopping therapy. This work prompted Shaw to suggest that LHRH analogues should be used as an adjunct to the surgical management of fibroids. 2 The aim of the present study was to measure the effect of a single implant of goserelin on large fibroid masses prior to elective surgery, to determine its effect PATIENTS AND METHODS Six patients, aged 42 -50 years, parity 0 -2, were recruited to the study from the gynaecological clinic of the Ulster Hospital. All had menorrhagia, dysmenorrhoea and generalised lower abdominal pain and pressure. On clinical examination each patient had a firm abdominal mass equivalent in size to a 16 -20 week pregnancy. Clinically these were fibroid masses and ultrasound examination supported this diagnosis. The patients were offered abdominal total hysterectomy and bilateral salpingo -oophorectomy with postoperative hormone replacement therapy as the treatment of choice. Each was given an admission date within 4 -8 weeks. After informed consent for the present study was obtained, each patient received a 3 -5 mg goserelin implant into the anterior abdominal wall after local infiltration with 1 % lignocaine. They were then reviewed weekly for ultrasonic assessment of the maximum length (a), depth (b) and width (c) of the tumour. Measurements (a) and (b) were taken in the longitudinal plane and (c) in the transverse plane. Ultrasound scanning was performed on an Ultramark 4 machine by one observer. After obtaining a picture of what was regarded as the maximum size of the mass, the ultrasonographer freeze -framed the picture and turned the screen away. The second observer performed the measurements and obtained hardprint copies of these. Fibroid (Table 1) , the shrinkage being obvious within two weeks in all cases and maximum by four weeks (Fig 1) . This reduction was evident on palpation. The shrinkage coincided with the postmenopausal levels of oestradiol ( < 50 pmol/l) achieved with the treatment. These levels were reached in all cases by four weeks from implantation (Fig 2) . These coincided with hypogonadotrophic levels of FSH and LH (< 2 IU/I). The estimated volume by scan prior to surgery corresponded to within 5 -14% of the actual volume of the surgical specimen (minus ovaries and tubes) as determined by fluid displacement (Table 11 ). The ultrasound volumes were all under -estimated. Concern has been expresed regarding the potential side effects of the LHRH agonists. The only side effects recorded by our patients were tolerable hot flushes and these were offset by relief of pain and pressure. In theory, long -term usage of a LHRH analogue could be associated with bone loss or coronary artery disease.
Our patients did not show any change in serum calcium or alkaline phosphatase during the short period of this study. Van Leusden and Dogterom did not find any bone loss following six months of continuous treatment with a LHRH analogue. '3 We contend that this chemosurgical approach to large fibroids is safe, effective and beneficial to the patient. One implant produces significant benefits and this schedule could be incorporated into standard clinical practice. Close follow -up of patients preoperatively seems unnecessary as there are few side effects.
